Literature DB >> 25225505

Prevalence and Susceptibility Pattern of Multi Drug Resistant Clinical Isolates of Pseudomonas aeruginosa in Karachi.

Fouzia Khan1, Adnan Khan2, Shahana Urooj Kazmi3.   

Abstract

OBJECTIVE: To determine the frequency and susceptibility pattern of multi-drug resistant (MDR) Pseudomonas aeruginosa isolated from clinical specimens in Karachi.
METHODS: This cross sectional study was conducted in Microbiology Department, University of Karachi, from January 2012 to January 2013. Clinical specimens were collected from different hospitals of Karachi. Clinical isolates were identified by standard and specific microbiological methods. The antibiotic susceptibility pattern was determined by Kirby Bauer Disc diffusion method. Clinical and Laboratory Standards Institute (CLSI) guidelines were used to determine the results.
RESULTS: The frequency of MDR P. aeruginosa isolated from different clinical specimens was found to be 30%. Amikacin was found to be the most effective antibiotic, followed by Co-trimaxazole and Quinolones.
CONCLUSION: Antibiotic resistant P. aeruginosa are emerging as a critical human health issue. There is an urgent need to resolve the issue by taking some preventive measures. Combined efforts of health care professionals and researchers are required to educate people about the proper use of antibiotics and other infection control measures.

Entities:  

Keywords:  Amikacin; Co-trimaxazole; Multi Drug resistant Pseudomonas aeruginosa; Quinolones

Year:  2014        PMID: 25225505      PMCID: PMC4163210          DOI: 10.12669/pjms.305.5400

Source DB:  PubMed          Journal:  Pak J Med Sci        ISSN: 1681-715X            Impact factor:   1.088


INTRODUCTION

Antibiotic resistance is one of the alarming issues, affecting human health. There are various factors responsible to the emergence of resistance such as, misuse and overuse of antibiotics, patient related factors, inappropriate prescriptions by the physicians, self medications especially young adults, use of broad spectrum antibiotics and synergistic combinations, un necessary promotions by pharmaceutical industry, untrained staff in microbiological testing laboratories, lack of awareness with the new guidelines recommended for antimicrobial testing etc.[1] Pseudomonas aeruginosa is one of the major cause of hospital acquired infections especially patients admitted in ICU (Intensive Care Unit).[2] Data presented by the Center for Disease Control and Prevention(CDC), Nosocomial Infection Surveillance System, in the USA, P.aeruginosa cause diverse variety of infections and was found to be the second most common cause of nosocomial pneumonia, the third most common cause of nosocomial urinary tract infections, and the eighth most common cause of nosocomial bacteraemia.[3] Majority of the infections caused by P. aeruginosa are often severe, life threatening and are un treatable because of the higher resistance to antimicrobial agents and lack of new drugs development.[4],[5] Over all, resistance rates keep on increasing and differ according to epidemiology of different geographical locations. Multi drug resistance is getting common phenomenon and resistance of almost all anti-pseudomonal agents are being reported worldwide. There is debatable issue of using combination of antimicrobial agents against complicated infections, but usually single antimicrobial agents are recommended for uncomplicated infection.[2] Development of antimicrobial resistance limits the therapeutic options that leads to high mortality and morbidity.[6] Emergence of antibiotic resistance in P. aeruginosa has been an increasing trend. There is diversity of definitions to describe MDR isolates of P. aeruginosa. According to the different studies, the term MDR P. aeruginosa has been described as resistance to at least three antibiotics from a variety of antibiotic classes, mainly Aminoglycosides, Penicillins, Carbapenems, Cephalosporins and Quinolones.[7] Hidron et al, considered MDR P. aeruginosa when resistant to only a single important anti -P. aeruginosa agent.[8] Current study followed the definition of MDR P. aeruginosa as stated by European Center for Disease Prevention and Control (ECDC) and Centre for Disease Control and Prevention (CDC), where MDR P. aeruginosa was defined as the one that has acquired non susceptibility to atleast one agent in three or more categories of antimicrobials.[9] The present study was conducted to detect the antibiotic susceptibility profile and prevalence of MDR P. aeruginosa isolated from different clinical samples, collected from different hospitals of Karachi.

METHODS

This cross sectional study was conducted in Microbiology Department, University of Karachi, from January 2012 to January 2013. Clinical samples (urine, pus, wound swabs, ascitic and bronchial fluid, blood) were collected from different hospitals of Karachi. Overnight culture was further incubated on shaking water bath for 2 h, the turbidity of inocula was matched with 0.5 MacFarland standard suspension. McFarland standards were prepared by adding specific volumes of 1% Sulphuric acid and 1.175% Barium chloride. McFarland standard 0.5 contain 99.5ml of 1% Sulphuric acid and 0.5ml of 1.175% Barium chloride. The turbidity of standard was comparable to bacterial suspension containing 1.5 × 108 CFU/ml. Agar plates were prepared using dehydrated media according to the instructions of the manufacturers. After autoclaving, media was allowed to cool down to ~450C, then poured in the Petri plates. These Petri plates can be safely stored in refrigerator with proper precautions for about 2 weeks. : Clinical isolates were identified by standard methods. They were inoculated on Blood agar (Oxoid), Mac Conkeys agar (Oxoid) and Cystine lactose electrolyte deficient agar (Oxoid). Isolates were identified on the basis of colony morphology, Gram staining and biochemical tests including Catalase, Oxidase, Sulfide, Indole, Motility, Citrate, Urea, TSI reaction, Pyocinin production and Lactose Antimicrobial activity was performed by using NCCLS standards.[10] Modified Kirby-Bauer disc diffusion method was used for antimicrobial testing. Antibiotic disc of Piperacillin/ tazobactam (110µgm),Imepenem (10µgm), Meropenem (10µgm), Cefuroxime (30µgm), Cefipime (30µgm), Ceftazidine (30µgm), Amikacin (30µgm), Gentamicin(10µgm), Ciprofloxacin (5µgm), Nalidixic acid (30µgm), Co-trimoxazole(5µgm), were purchased from Oxoid. Mueller Hinton plates were seeded with 0.5 MacFarland suspension matched turbidity inocula and antibiotic disc were placed on them. Results were interpreted after 24 hours of incubation at 370C by measuring zones of inhibition around discs. Experiments were conducted in triplicate to authenticate the results. Statistical analysis was performed by SPSS version 17. Frequency of MDR P. aeroginusa and percentage of resistant antibiotics were calculated.

RESULTS

P. aeroginusa were isolated from clinical samples. Out of 100 isolates, 30 were found to be MDR P.aeroginusa (Table-I). ATCC P. aeruginosa 27853 was used as positive control.
Table-I

Distribution of MDR P. aeruginosa in Clinical Samples

S. No Samples No. of Isolates Percentage
1Pus1033.3
2Wound swabs826.6
3Bronchial Fluid723.3
4Urine310
5Blood26.6
P. aeruginosa was confirmed by negative sulphide and lactose tests and positive results in rest of biochemical identification tests. The maximum number of MDR P. aeroginusa were isolated from pus samples (33.3%), followed by wound swabs (26.6%), bronchial fluid (23.3%), urine (10%) and blood samples (6.6%), as represented in Table-I. The resistance patterns of MDR P.aeruginosa against antimicrobial agents are presented in Table-II. Highest resistance was observed against Cephalosporin group of antibiotics. While, more than 50% of isolates subjected to antimicrobial testing were found resistant to Piperacillin/Tazobactum. Around 40% of isolates were resistant against Carbapenems. While 90% of the isolates were sensitive to Amikacin.
Table-II

Antibiogram of MDR P. aeruginosa

S. No Antibiotics No. of MDR P.aeroginosa Resistance Percentage Resistance of MDR P.aeroginosa
1Piperacillin/Tazobactum1756.6
2Imepenem1240
3Meropenem1240
4Cefuroxime30100
5Cefixime30100
6Ceftriaxone2686.6
7Cefepime2376.6
8Amikacin310
9Gentamicin930
10Ciprofloxacin826.6
11Nalidixic acid825
12Co-trimoxazole620
Distribution of MDR P. aeruginosa in Clinical Samples Antibiogram of MDR P. aeruginosa

DISSCUSSION

Infections of multi drug resistant P. aeruginosa are increasing worldwide. It is an important pathogen frequently involved in various infections especially in severely or terminally ill patients.[11],[12] Altered target sites, bacterial efflux pumps, enzyme production or inhibition, loss of membrane protein, etc are different mechanisms mediated by multidrug-resistance (MDR) P.aeruginosa.[3] This study revealed the susceptibility pattern of antibiotics used and the frequency of MDR P. aeruginosa found in the city of Karachi. The present study showed a 30% frequency of MDR P. aeruginosa, while Gill et al, reported a 22.7% incidence in Islamabad.[13] Another study was conducted in Peshawar in 2009 by Farhatullah et al, which reported 29% prevalence of MDR P. aeruginosa.[14] Increasing resistance of beta-lactam in nosocomial P. aeruginosa has become a serious threat particularly against third and fourth generation Cephalosporins, is of major concern. There are a lot of molecular mechanisms to develop resistance against these antibiotics; generation of extended-spectrum beta-lactamases (ESBL), by incorporation of bla genes in integrons and inability of porin genes to enhance their expression level and/or alteration of antibiotic target sites.[15] Present study showed that P. aeruginosa was found to be highly resistant against cephalosporin group of antibiotics. Study reported by Wang et al, explained the absolute resistance of Ampicillin, Cephazolin, Cefuroxime and Cefotaxime, which is in accordance with our results.[16] Our study was also supported by Hamza et al, exhibited 100% resistance against Cefixime.[17] While Jombo et al, reported 86% susceptibility of P. aeruginosa against cefurixime.18 Carbapenems the most significant group of antibiotics against MDR P. aeruginosa but the development of Carbapenems resistance is becoming a challenge for health care professionals and limited the therapeutic options. Sufficient measures are required to prevent the spread of Carbapenemase encoding gene to other bacteria.[19] The current study demonstrated that 60% P. aeruginosa were resistant against Carbapenem antibiotics (Imepenem, Meropenem). Rodríguez-Martínez JM et al, showed that 87% of strains of P. aeruginosa were resistant against Imepenem.[19] Another study reported 100% resistance against Carbapenems,[20] it is very obvious that efficacy of this particular antibiotic is declining. Clonal spread contributes lesser importance in the statistics and epidemiology of infections caused by P. aeruginosa, and the main mechanism associated with increased resistance to Imipenem was reduced expression of OprD (outer membrane protein) found in the isolates.[19] Fluroquinolone compounds are one of the important antimicrobial agents that have been used for variety of infections. New groups of Fluroquinolone are beneficial against Gram-negative and Gram-positive bacteria as far as older Fluroquinolones are concerned, they were effective against aerobic Gram-negative bacteria.[21] Present study showed 75% sensitivity against Ciprofloxacin and Nalidixic acid, while 100% resistance against Ciprofloxacin was exhibited in one study.[20] Similarly, 87.8% resistance was also claimed by another study.[13] Abdallah et al, reported 100% resistance to Nalidixic acid.[22] Aminoglycosides is a significant member of broad spectrum antibiotics with a peculiar structure of an aminocyclitol ring. They are outstandingly active against aerobic and facultative aerobic Gram-negative bacteria. They mainly act by inhibiting protein synthesis and break cell membrane.[23] The current study explored that anti P. aeruginosa effect of Amikacin was higher than Gentamicin. Amikacin was constructed as a weak candidate for the enzymes that are responsible to bring chemical modifications but some organisms have developed specific enzymes to inactivate Amikacin.[24] One study declared 21% resistance against Aminoglycoside.[21] Moreover, one more study explained 83% resistance to Amikacin. The resistance of clinical isolates to Aminoglycoside antibiotics varies with the specific drug, the microorganism, its mechanism of resistance, the geographic area and many other factors.[25] Cotrimaxazole is the synergistic combination of Trimethoprin and Sulfomethaxazole. This study showed 20% resistance of P.aeruginosa against Cotrimaxazole but in contrary 100% resistance was documented in Libya22 as well as 47% resistance reported by study conducted in Nigeria.[18] This study indicated Amikacin as an efficient treatment of choice against MDR P. aeruginosa among all the tested antibiotics.

CONCLUSION

The emergence of MDR P. aeruginosa and its continual spread is out of debate. Antibacterial research is not sufficient to keep pace with the clinical challenges of MDR bacterial crises. Lack of new drug pipelines and other issues are leaving disastrous consequences on the health of community. To overcome such issues, new therapeutic agents with maximum efficacy, lesser toxicity and cost effective in nature are urgently needed. Epidemiological studies and strict laws regarding antibiotic policies should be constructed to limit the unnecessary use of antibiotics so that spread of multidrug resistance can be avoided.

Authors contribution:

Dr. Fouzia Khan designed and performed the study Dr. Adnan Khan did statistical analysis and editing of manuscript. Dr. Shahana Urooj Kazmi supervised the study from each and every step starting from sampling, data collection, experimental work, results and writing of this manuscript.
  20 in total

Review 1.  Mechanisms of action and resistance of older and newer fluoroquinolones.

Authors:  D C Hooper
Journal:  Clin Infect Dis       Date:  2000-08       Impact factor: 9.079

2.  Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes.

Authors:  I Chatzinikolaou; D Abi-Said; G P Bodey; K V Rolston; J J Tarrand; G Samonis
Journal:  Arch Intern Med       Date:  2000-02-28

3.  Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa.

Authors:  Vincent H Tam; Kai-Tai Chang; Kamilia Abdelraouf; Cristina G Brioso; Magdalene Ameka; Laurie A McCaskey; Jaye S Weston; Juan-Pablo Caeiro; Kevin W Garey
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

Review 4.  Versatility of aminoglycosides and prospects for their future.

Authors:  Sergei B Vakulenko; Shahriar Mobashery
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

Review 5.  Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.

Authors:  Philip D Lister; Daniel J Wolter; Nancy D Hanson
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

6.  Multiple resistant Pseudomonas aeruginosa in contemporary medical practice: findings from urinary isolates at a Nigerian University Teaching Hospital.

Authors:  G T A Jombo; P Jonah; J A Ayeni
Journal:  Niger J Physiol Sci       Date:  2008 Jun-Dec

7.  Antimicrobial susceptibility and ESBL prevalence in Pseudomonas aeruginosa isolated from burn patients in the North West of Pakistan.

Authors:  Farhat Ullah; Salman Akbar Malik; Jawad Ahmed
Journal:  Burns       Date:  2009-06-06       Impact factor: 2.744

8.  The growing challenge of antimicrobial resistance in the South-East Asia Region--are we losing the battle?

Authors:  Rajesh Bhatia; Jai P Narain
Journal:  Indian J Med Res       Date:  2010-11       Impact factor: 2.375

9.  VIM-2-producing multidrug-resistant Pseudomonas aeruginosa ST175 clone, Spain.

Authors:  Esther Viedma; Carlos Juan; Jennifer Villa; Laura Barrado; M Angeles Orellana; Francisca Sanz; Joaquín R Otero; Antonio Oliver; Fernando Chaves
Journal:  Emerg Infect Dis       Date:  2012-08       Impact factor: 6.883

10.  [Changes of drug-resistance of Pseudomonas aeruginosa in pediatric intensive care unit].

Authors:  Li-jie Wang; Ying Sun; Wen-liang Song; Zhi-jie Zhang; Chun-feng Liu
Journal:  Zhonghua Er Ke Za Zhi       Date:  2012-09
View more
  7 in total

1.  Genomic Surveillance of Clinical Pseudomonas aeruginosa Isolates Reveals an Additive Effect of Carbapenemase Production on Carbapenem Resistance.

Authors:  Luke Diorio-Toth; Sidra Irum; Robert F Potter; Meghan A Wallace; Muhammad Arslan; Tehmina Munir; Saadia Andleeb; Carey-Ann D Burnham; Gautam Dantas
Journal:  Microbiol Spectr       Date:  2022-05-31

2.  In vitro comparison of cytotoxic and antibacterial effects of 16 commercial toothpastes.

Authors:  Jannan Ghapanchi; Fereshteh Kamali; Afagh Moattari; Sara Poorshahidi; Esmaiel Shahin; Fahimeh Rezazadeh; Hooman Khorshidi; Samira Jamshidi
Journal:  J Int Oral Health       Date:  2015-03

3.  Antimicrobial susceptibility patterns of clinical isolates of Pseudomonas aeruginosa isolated from patients of respiratory tract infections in a Tertiary Care Hospital, Peshawar.

Authors:  Abdul Samad; Tanveer Ahmed; Afaq Rahim; Abdul Khalil; Iftikhar Ali
Journal:  Pak J Med Sci       Date:  2017 May-Jun       Impact factor: 1.088

4.  Combination Effect of Silver Nanoparticles and Histone Deacetylases Inhibitor in Human Alveolar Basal Epithelial Cells.

Authors:  Sangiliyandi Gurunathan; Min-Hee Kang; Jin-Hoi Kim
Journal:  Molecules       Date:  2018-08-15       Impact factor: 4.411

5.  High frequency and molecular epidemiology of metallo-β-lactamase-producing gram-negative bacilli in a tertiary care hospital in Lahore, Pakistan.

Authors:  Noor Ul Ain; Anam Iftikhar; Syeda Sadia Bukhari; Samyyia Abrar; Shahida Hussain; Muhammad Hayat Haider; Farhan Rasheed; Saba Riaz
Journal:  Antimicrob Resist Infect Control       Date:  2018-11-03       Impact factor: 4.887

6.  Multidrug Resistant Pseudomonas aeruginosa in Iran: A Systematic Review and Metaanalysis.

Authors:  Hamid Vaez; Amin Salehi-Abargouei; Zahra Rashki Ghalehnoo; Farzad Khademi
Journal:  J Glob Infect Dis       Date:  2018 Oct-Dec

7.  Epidemiology and high incidence of metallo-β-lactamase and AmpC-β-lactamases in nosocomial Pseudomonas aeruginosa.

Authors:  Maria Muddassir; Sadaf Munir; Almas Raza; Ahmad Basirat; Muddassir Ahmed; Umar Farooq; Syed Shoaib Ahmed; Syed Zeeshan Haider Naqvi
Journal:  Iran J Basic Med Sci       Date:  2021-10       Impact factor: 2.699

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.